Pfizer names new worldwide R&D president
NEW YORK Pfizer has named Mikael Dolsten as its president for worldwide research and development, the drug maker said Wednesday.
Dolsten previously led research and development at Wyeth from May 2008 until Pfizer acquired it; after that, he was named president of Pfizer’s biotherapeutics research and development. Dolsten previously worked in research and development leadership positions at Boehringer Ingelheim and AstraZeneca.
In his new position, Dolsten will lead all research at Pfizer and lead development of drugs through mid-stage clinical trials.